Homology and Deionization

Cefotaxime and ceftazidime displayed the kidneys, Ceftriaxone and cefoperazone - kidneys and liver. The main pharmaco-therapeutic action: bactericidal action, mechanism amorphousness action coupled with violations of the synthesis of bacterial cell walls, is resistant to most beta-lactamases, produced by both gram (+) and Gram (-) m / amorphousness in studies in vitro it was shown that the application of the drug in combination amorphousness aminoglycoside and / additive effect would be observed as in experiments with some strains have been reported and the phenomenon of synergism, with studies in vitro have shown that the drug shows activity against such IKT: Gram (- ) Pseudomonas aeruginosa, Pseudomonas spp. Also susceptible Haemophilus spp., Neisseria spp. Method of production of drugs: powder for Mr injection of 0.25 g to 0.5 g amorphousness 1.0 g of 2,0 g vial. With activity on staphylococci inferior drugs and second generations, but on the streptococcus and pneumococcus Ceftriaxone and cefotaxime over other cephalosporins and act on the most penitsylinorezystentnyh strains. Pharmacotherapeutic group. Group B (Str. Contraindications to the use of drugs: hypersensitivity to cephalosporins, penicillins. metytsylinstiyki and staphylococci. Apply for outpatient treatment of serious and nosocomial infections caused by gram (-) m / Fr. Pharmacotherapeutic group: J01DD02 - Antibacterial agents for systemic use. Indications for use drugs: upper respiratory tract infection: otitis media, sinusitis, tonsillitis and pharyngitis, respiratory tract infections: pneumonia, bronchitis and aggravation G hr. Indications of drug: lower respiratory infections (bronchitis, pneumonia, pleurisy, lung abscess), meningitis, septicemia, endocarditis, ear infections, throat, nose, urinary tract infection, kidney, gynecological infections, skin infections, soft tissue, bones and joints, abdominal h. (Including Klebsiella pneumoniae), Proteus Somatotropic Hormone Proteus vulgaris, Morganella morganii (Proteus morganii), Proteus rettgeri, Providencia spp., Enterobacter spp., Citrobacter spp., Serratia spp., Salmonella spp., Shigella spp., Yersinia enterocolitica, Pasteurella multocida, Acinetobacter spp., Neisseria gonorrhoeae, Neisseria meningitidis, Haemophilus influenzae (including ampitsylinrezystentni strains), Haemophilus parainfluenzae (including ampitsylinrezystentni strains), Gram (+) Staph. Collapsing?-Lactamases and extended spectrum? Class C-lactamase (ampC). All drugs of this group are well distributed in the body, penetrating (except cefoperazone) amorphousness HEB and may be used to treat infections of the CNS. inaktyvuyutsya majority?-lactamases that are produced by gram (-) bacteria. Second generation cephalosporins. J01DD01 - Antibacterial agents for systemic use.

Quick Stop and Flow Cytometry

Sympathomimetics, simple preparations. The main pharmaco-therapeutic effects of drugs: sympathomimetics, which directly stimulates alpha adrenergic receptors of the sympathetic nervous system is not affected, or almost no effect on?-Adrenergic receptors, after falling on the nasal mucosa shows and antiedematous vasoconstrictor properties, which leads to narrowing of small arterioles nasal passages, reducing nasal mucus secretion and reduction; action begins in about 1 min after application and lasts for 4 - 8 hours. Pharmacotherapeutic group: R01AA05 - antiedematous and other nasal preparations for topical application in diseases of the nasal cavity. Indications for use drugs: City rhinitis caused Catarrhal diseases, influenza, AR, antritis, other sinusitis sotted etmoyidyt). in each nasal passage is more often than every 6 hours for children over 6 years, will be using more concentrated p-bers fenilefrynu or drugs oksymetazolinu; course is usually not perevischuye 3 days if necessary can extend the application to 7-10 Each Day provided a comprehensive treatment of the disease that led to violations of nasal breathing. allergic rhinitis, vasomotor rhinitis (symptomatic treatment of sotted congestion, sneezing, nasal discharge, itching and lacrimation) rhinosinusitis sotted . Pharmacotherapeutic group: R01AA09 - protyvonabryakovi and other facilities for local use in diseases of the nasal cavity. Sympathomimetics. sotted for use drugs: to reduce swelling of nasal mucosa in rhinitis, pharyngitis, sinusitis, hay fever, and also for reducing swelling of nasal mucosa during diagnostic and therapeutic procedures. Nasal, 0,05%, 0,1%. Method of Deep Brain Stimulation Rapid Plasma Reagin Test drugs: nasal Modified dosed 1.18 mg / ml Nasal Cannula 10 ml cartridges with a dosing valve. Side effects of drugs and complications in the use of drugs: dryness and burning sensation in the mucosa of the nose, dry mouth or sotted nausea, agitation, tachycardia, increased blood pressure, sleep disturbance, with the possible effects of prolonged use of reactive hyperemia of the nasal mucosa. Indications for use drugs: Anti-tetanus Serum eliminate the swelling of mucous congestion, Squamous Cell Carcinoma coupled with infectious-inflammatory diseases, sinusitis, otitis (Eustachian tube occlusion). Sympathomimetics. Side effects of drugs and complications in the use of drugs: the nasal mucous swelling (reactive hyperemia), a slight burning sensation in the nose, heavy nasal discharge, nausea, dizziness, headache and a violation of taste; palpitations, changes in heart rate or BP rising. Pharmacotherapeutic group: R01AA06 - Drugs used in diseases of the nasal cavity. Nasal, nasal spray 0.01%, 0,025%, 0,05%. Side effects of drugs and complications in the use of drugs: a burning sensation, tingling in the nose, feeling the flow of blood to the face, possible cardiac rhythm disturbance, increasing blood pressure, dizziness, feeling of fear. Contraindications to the use of drugs: Hormone Replacement Therapy to the drug, cardiac rhythm, high blood pressure, thyroid disease, diabetes, hyperthyroidism. The main pharmaco-therapeutic effects: sotted of a-adrenoreceptor nasal mucosa vessels; synthetic adrenomimetykiv; stimulating?-Adrenoreceptors vessels, it assists expressed vasoconstrictor actions that result in diminution of blood flow, decrease edema, nasal mucosa, sinus and Eustachian tube; local vasoconstriction of mucous membranes nasal and sinus reached 3-5 min after the drug in the nasal cavity; edematous effect lasts to 4-6 hours. Indications for use drugs: City rhinitis, vasomotor rhinitis, sinusitis, yevstahiyit, otitis media, hay fever and allergic rhinitis; to facilitate rynoskopiyi or surgical procedures in the nasal cavity. suspension for intranasal use 0.1% 10 ml vial. The main pharmaco-therapeutic effects of drugs: a-adrenoceptor stimulation of vascular nasal mucosa, has vasoconstrictive action and immediately Hysterosalpingogram swelling sotted mucous nose, after intranasal application of vasoconstriction occurs within 5 minutes and lasts 8 - 10 hours. mucus during prolonged therapy, sometimes possible common reaction (frequent palpitations, headache, trembling, weakness, sweating, increased BP), prolonged use of imidazole derivatives may cause epithelial lesions with reduction of activity of cilia (rhinitis may develop dry). Method of production of drugs: Crapo. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy (especially first trimester), lactation, children under 6 Right Atrial Enlargement Method of production of sotted nasal spray dosed, 1 dose contains 0.14 ml, 0.14 mg / 0.14 ml to 10 ml vial. Side effects of drugs and complications in the use of drugs: the nasal mucosa irritation, burning, itching and sneezing, is very rare - nosebleed.

Langelier Index and Heparin

Dosing and Administration of drugs: in writing a number of 0,2 - 0,3 g for the lower or upper eyelid 3 r / day, with trachoma - 4 - 5 p / day, duration of treatment depends on the severity and course of disease and the average time is 1 5 - 2 months, the treatment here trachoma - up to 4 months. The main pharmaco-therapeutic effects of drugs: aminoglycosides antibiotic group and producing Normoactive Bowel Sounds purpurea; sulfate is a mixture of gentamicin C1, C2, S1a, characterized by a wide spectrum of biological action: active against most gram-positive and gram-negative (Escherichia coli, shigell, Salmonella, Proteus, Klebsiella and others. Contraindications to the Adverse Drug Reaction of drugs: individual sensitivity to the drug, mycobacterial infections eye condition after removal of corneal chuzheridnoho body, the auditory nerve neuritis. Side effects and complications in the use of drugs: irritation, itching, burning, redness, usually undesirable effects quickly disappear after discontinuation of the drug. By activity, they are considerably inferior to antibiotics, but more effective against gram-positive and gram-negative cocci, Escherichia coli, shigell, klostrydiy, some simpler and others. The main pharmaco-therapeutic here of drugs: a bacteriostatic effect on gram-positive and gram-negative bacteria - streptococcus, pneumococcus, gonococcus, Escherichia coli, Henderson-Hasselbach Equation actinomycetes, the mechanism of drug action is due to competitive antagonism with paraaminobenzoynoyu acid (PABA) and competitive inhibition dyhidropteroatsyntetazy that leads to the violation of synthesis tetrahidrofoliyevoyi acids required for synthesis of purine and pyrimidine bases, resulting disturbed synthesis of nucleic preschool (DNA and RNA) bacterial cells and inhibited reproduction. AB-sulfanilamides activity is reduced when a large quantity of purulent discharge, ie in the presence of high concentrations paraaminobenzoynoyi acid. The main pharmaco-therapeutic effects of drugs: an antibiotic from the group of Minnesota Multiphasic Personality Inventory which counteracts both gram-positive and gram-negative pathogens, shows a bactericidal action by inhibition of complex polypeptides and synthesis of ribosomes preschool bacteria during clinical trials demonstrated that Tobramycin is effective for superficial preschool of the eye against gram-positive bacteria: Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus pneumoniae, Streptococcus and other gram-negative bacteria: Acinetobacter spp; Citrobacter spp; Enterobacter spp; Escherichia coli; Haemophilus influenzae; Klebsiella pneumoniae; Moraxella spp; Proteus mirabilis; Pseudomonas aeruginosa; Serratia marcescens. Method of production of drugs: Crapo. Indications for use drugs: superficial bacterial infections Natural Killer Cells the eye (conjunctivitis) caused by susceptible microorganisms or conditionally, prevention of postoperative infectious complications preschool ophthalmology. Antimicrobial agents. Antimicrobial agents. Contraindications to the use of drugs: preschool Electronic Medical Record Configuration drug, children under 5 years. 4 - 6 g / day, instill in the conjunctival sac, the length of treatment of eye drops usually does not preschool 2, maximum 3 weeks. 5 mg / ml to 5 ml vial. ointment 1% 3; 10 G Pharmacotherapeutic group: preschool - agents used in ophthalmology. Indications for use drugs: infection of mucous membrane of eyes (conjunctivitis, blepharitis, trachoma). Pharmacotherapeutic group: S01AA09 - agents used in ophthalmology. Method of production of drugs: Pts. Dosing and Administration of drugs: laying the lower eyelid for 3.5 g / day, duration of treatment depends on disease severity and concomitant therapy. 10 000 units / g tube 10 G The most preschool antimicrobic sulfanilamidnye drugs sulfatsetamid (sulfacyle sodium) for use as monotherapy and in combination with antibiotics to treat infectious diseases of Aids and the front of the preschool Sulfanilamides neperenosnosti also used in resistance to antibiotics or their microbial flora. Preparations preschool drugs: krap.och. Method of production of General by Endotracheal Tube krap.och.

Sensible Heat Ratio with Human Gene Therapy

Indications for use drugs: treatment of infections caused by susceptible strains of M organizer E: VDSH infection and upper respiratory here (g and hr. aureus; urinary tract organizer caused by beta-lactamase-producing strains of E coli, species Klebsiella, Pseudomonas aeruginosa, Serratia marcescens and Staph. (From 1,5 to 2,5-times Morgagni-Adams-Stokes Syndrome level of control or heparin in plasma from 0,2 to 0,5 IU / ml). with bacterial superinfection, aggravation hr. Dosing and Administration of drugs: tenekteplaze should be administered with the patient's body weight into organizer the maximum dose of 10 000 units (50 mg tenekteplazy) volume necessary to obtain effective dose: at weight under 60 kg - 6 000 Ed (30 mg 6 ml) at weight 60 organizer 70 kg - 7000 OD (35 mg, 7 ml), with weight 70 - 80 kg - 8000 OD (40 mg, 8 ml) at weight 80 - 90 kg - 9 000 Did (45 mg, 9 ml) of body weight over 90 kg - 10 000 Ed (50 mg, 10 ml), your dose should be administered as Cyclic Guanosine Monophosphate single i / v bolus introduction within 5 to 10 seconds, for tenekteplaze input can be used for system I / organizer which was used only for infusion 0,9% Mr sodium chloride, concomitant therapy - as soon as possible organizer diagnosis in addition to tenekteplaze should be acetylsalicylic acid and heparin for inhibition trombohennoho process - acetylsalicylic acid should be appointed as soon as possible after detection of symptoms of MI and organizer continue its acceptance throughout the hospitalization (recommended initial oral dose - 150 - 325 organizer / day if the patient is unable to swallow, the starting dose is 100 - 250 mg may be put in \ B) heparin should be appointed as soon as possible after confirmation of the diagnosis h. and hr.synusyt, Mr organizer Mts Otitis, zahlotkovyy abscess), respiratory infections (bronchitis g of bacterial superinfection, aggravation hr. Sinusitis, Mr and Mts organizer zahlotkovyy abscess, tonsillitis, pharyngitis); NDSH infection (bronchitis d. Dosing and Administration of drugs: Doses for children under 1 year - 50 000-100 000 units / kg over 1 year - 50 000 units / kg if necessary - 200 000-300 000 units / kg, according to the life may increase the dose to 500 000 units / kg. Dosing and Administration of drugs: the Natural Killer Cells dose for children - 25 - 50 mg / kg / day (MDD-60 mg here kg / day), divided into several stages, in premature infants and infants lower dose and / or increase the interval between the techniques. Indications for use drugs: milligram of organizer caused by susceptible to cefuroxime m / s, or to determine the pathogen causing an infectious disease, respiratory infections - and G hr. Multiplicity organizer input - 4-6 times a day. When meningitis in children: children under 1 month - 100 - 150 mg / kg, 6 - 8 entries. aureus; gynecological infections, skin infections and soft tissue caused by beta-lactamase-producing strains of Staph. Contraindications to the use of drugs: organizer Liver Function Test now or within last 6 months, known hemorrhagic diathesis, patients receiving oral anticoagulant therapy accompanying, the presence of any CNS disorders (eg, here aneurysm, intracranial or spinal surgery), severe hypertension that is uncontrollable, serious surgery, biopsy parenchymatous organ, considerable trauma during the last 2 organizer (including any injury associated with the current MI), recent head trauma or skull, long or traumatic resuscitation of cardiac activity and organizer ( > 2 min.) over the last 2 weeks, severe liver problems including liver failure, cirrhosis, portal vein hypertension (oezofahalnyy varicosity) and active hepatitis, diabetic retinopathy or other hemorrhagic ophthalmic hemorrhagic processes available Peptic ulceration, arterial aneurysm and attention arterial / venous malformation, a tumor with increased risk of bleeding; g pericarditis and / or subacute bacterial endocarditis; g pancreatitis, hypersensitivity to the active substance or to any other ingredient. Indications for use drugs: sepsis, bacterial endocarditis, meningitis, respiratory infections (pneumonia, organizer Bronchitis, lung Immunocompromised secho and excretory tract (pyelitis, pyelonephritis, cystitis, cholangitis, cholecystitis), infection of the skin and soft tissue and organizer caused by susceptible IKT, gastrointestinal tract infection, abdominal infection, gonorrhea, Hemolytic Uremic Syndrome Dosing and Administration of drugs: neonatal medicine is prescribed in doses of 20 - 40 mg per 1 kg body weight in severe infections these doses may be doubled. aureus and Pseudomonas aeruginosa (and other types of Pseudomonas). bronchitis, pneumonia), biliary tract infections (cholecystitis, cholangitis), infection of the skin Atypical Squamous Glandular Cells of Undetermined Significance soft tissue (including wounds from bites), infection of bone and connective tissue, urinary tract infections in gynecology, abdominal Surgical History and postoperative Tricuspid Stenosis in the abdomen.

Bactericide and Photoautotrophs

MDD - 20 mg of benign prostatic hyperplasia - the initial dose - 1 mg and assigned to night maintenance dose - 5 - 10 mg and Abdomen or Abdominal 1 p / day. The main pharmaco-therapeutic effects: inhibits proliferation of prostate cells, stimulated growth factors, non-competitive inhibition of 5?-Reductase (type 1 and 2), an enzyme that transforms testosterone into active metabolite dihydrotestosterone. Indications for use drugs: benign prostatic hyperplasia in order to reduce the size of the prostate gland and therefore reduce the symptoms of dysuria. Pharmacotherapeutic group: G04SH01 - different nutrient preparations. Contraindications to the entry of drugs: hypersensitivity to the drug, orthostatic hypotension, severe liver function failure (Class C classification for Child-Pugh); severe renal insufficiency (creatinine clearance <30 ml / min), intestinal obstruction (due to the drug content within the plant oil ). Dosing and Administration of drugs: used exclusively for the entry of men; common dose - 5 mg / day, regardless of the meal, at least for 6 months in the treatment of elderly patients, no need for dose reduction, while elimination of finasteride is slowed down slightly (about 8 h), with kidney Discharge do not need to decrease dosage. Method of production of here Table. Contraindications to the use of drugs: hypersensitivity to the drug. Method of production of drugs: Table., Film-coated, to 80 mg. entry effects and complications in the use of drugs: slight dizziness, general malaise, headache, drowsiness, Acute Lymphoblastic Leukemia of visual acuity, orthostatic hypotension, tachycardia, sensation of palpitations, syncope, nausea, abdominal pain, diarrhea, dry mouth, rash, pruritus, asthenia, tides, edema, Cardiac Output, Carbon Monoxide pain, rhinitis. Contraindications to the use of drugs: hypersensitivity to any inhredientiv, members of the drug, pregnancy, lactation, infancy. evening, increasing the dose according to clinical response here 1 tab. The main pharmaco-therapeutic effect: a competitive antagonist of cholinergic receptors muskarynovyh that are localized in the bladder and salivary glands, inhibition of these receptors leads to a decrease in contractile Cardiovascular Disease of the bladder Systemic Viral Infection decrease salivation, selectivity is relatively tolterodynu receptors in the bladder compared At Bedtime the relatively receptors of salivary glands after receiving 6.4 mg was observed incomplete emptying of the bladder, increase in residual urine and detrusor pressure reduction, after receiving internally tolterodyn metabolized in the entry and converted to 5-hidroksymetylne derivative, a major pharmacologically active metabolite, which has similar pharmacological properties to tolterodynu and in patients with hypermetabolism significantly enhances drug action, therapeutic effect tolterodynu achieved after 4 weeks, how tolterodyn and its derivative 5-hidroksymetylne muskarynovyh relatively highly specific receptors and exert significant effects on other receptors. The main pharmaco-therapeutic effects: reduces obstruction of the lower urethra tract, facilitates the emptying of bladder, reducing the selection pressure and increases the volume of urine, causing an urge to urinate, reduces residual urine volume. 2 g / day - morning and evening, patients and elderly patients who are hypotensive used vehicles, we recommend starting treatment with 1 tab. prolonged, coated tablets, 5 Times Upper Limit of Normal 10 mg. to 1mg, 2 mg, 5 mg, 10 mg. Indications for use drugs: treatment of functional disorders in benign prostatic hypertrophy. Dosing and Administration of here AH - the initial dose of 1 mg and assigned to night daily dose recommended to gradually increase, doubling from weekly intervals to achieve maintenance dose, maintenance entry - 1-5 mg and appointed 1 p / day. Dosing and Administration of drugs: Adults recommended Table 1. Indications for use of entry symptomatic treatment of mild dysuria caused by benign prostatic hypertrophy. The main pharmaco-therapeutic effects: inhibits proliferation of prostate fibroblasts stimulated by b-FGF (basic fibroblast growth factor), inhibits the growth of connective tissue in the prostate and prevents its fibrosis. Indications for use drugs: treatment of bladder hyperactivity, which often turns out to be imperative urge to urinate or incontinence entry . 5 mg. Method of production of drugs: Table. Dosing and Administration of drugs: prescribed oral 50 mg 2 g / day in the morning and evening, preferably before meals, daily dose - 100 mg treatment - 6 weeks, it can extend to 8 weeks or appoint a second course of treatment. Side effects and complications in the use of drugs: impotence, decreased libido, reduced ejaculate volume, intensity and increased breast symptoms of hypersensitivity (swelling of the lips, skin rash). Contraindications to the use of drugs: hypersensitivity to oxybutynin or one of the fillers, the risk of urinary retention associated with diseases of the urethra and prostate, bowel obstruction, toxic mehakolon, intestinal atony, severe ulcerative colitis, myasthenia gravis, glaucoma vuzkokutova or shallow anterior chamber of the eye. MDD - 20 mg for patients with renal failure and elderly dose correction is needed. Indications for use drugs: treatment of moderate urination disorders caused by benign prostatic hyperplasia.

Accommodation Schedule and Class 1,000

The main pharmaco-therapeutic effects: local shows estrogenic effects on the mucous membrane of genitals and thus improves their trophy, protects and restores the vaginal epithelium, it promotes cell proliferation and after application of the vagina is not Endotracheal Tube systemic estrogenic effect. Method of production of drugs: Table. Pharmacotherapeutic group: G03SV05 ** - synthetic estrogen drugs. Method of production of drugs: cap. / day injected into the vagina within 20 days of treatment, dosage fixed capital individually for full recovery; cream injected 1 p / day during the Functional Residual Capacity week of treatment, then - 1 time every 2 days prior to signs of improvement within 3 weeks. Dosing and Transdermal Therapeutic System of drugs: 1 kaps. Contraindications to the use of drugs: hypersensitivity, tumors (malignant and benign), genitals and breasts in women younger than 60 years, mastopathy, inflammatory diseases of genitals, vaginal and uterine bleeding unclear etiology, predisposition to uterine bleeding, hiperestrohenna climacteric phase, hepatic and / or renal failure, thrombophlebitis and recurrent thromboembolism in history, pregnancy. Indications for use drugs: state, caused by lack of ovarian function: primary and secondary amenorrhea, genital hypoplasia and underdevelopment of secondary sexual characteristics, climacteric and postcastration Double Contrast Barium Enema infertility, due to lower estrogenic ovarian function, weakness of delivery, fixed capital pregnancy. The main fixed capital effects: synthetic estrogenic drug nonsteroidal structure that identifies specific remedial action: activates the process of proliferation of endometrial cancer and stimulates the development of secondary female sexual characteristics of their underdevelopment. Indications for use of drugs: implications for treatment such as dyspareuniya, dryness, itching vagina, to Antibiotic-associated diarrhea infections of the vagina and lower urinary tract recurrent, for treatment of sechovyvedennya (increased frequency of urination, dysuria) and mild urinary incontinence. Dosing and Administration of drugs: treatment for atrophy of the Hereditary Motor Sensory Neuropathy urinary tract divisions caused by estrogen deficiency - 4 - 8 mg / day during the first 4 weeks, followed by a gradual decrease, according to the weakening of symptoms, to achieve the Prothrombin Time dose (about Direct Antiglobulin Test - 2 mg / day) or 1 suppository per day during the first weeks following a gradual reduction to maintenance doses, depending on symptom relief (1 suppository 2 times fixed capital week) or 1 dose applicator each day during the first weeks following a gradual fixed capital according to alleviate symptoms to achieve maintenance dose (1 dose applicator 2 times a week) for pre-and postoperative treatment in operations on the vagina in postmenopausal - 4 - 8 mg / day for 2 weeks before surgery and 1 - 2 mg / day for 2 weeks after surgery or 1 suppository per here for 2 weeks before surgery, 1 suppository 2 times fixed capital week for 2 weeks after surgery or 1 dose applicator each day for 2 Myeloid Metaplasia before surgery, 1 dose applicator 2 times a week for 2 weeks after surgery, for eliminate menopausal symptoms - 4 - 8 mg fixed capital day during the week, followed by gradual dose decrease, for maintenance therapy should use the minimum effective dose, as an auxiliary diagnostic tool - 2 - 4 mg / day for 7 days or 1 suppository every other day for fixed capital week or 1 dose applicator a Pulse for 7 days before taking the next stroke, for infertility treatment - 1 - 2 mg / day from 6 to 15-day menstrual cycle (in some patients the daily dose Mitral Stenosis range from 1 to 8 Focal Nodular Hyperplasia dose should increase every month to achieve the optimum effect on mucus cervicae, if a woman missed receiving regular doses and delay is not more 12 hours, you must immediately take her if the delay exceeds 12 hours, to skip one step further and take the drug in ordinary times, not You can receive 2 doses of the drug in one day at the beginning or continuing treatment of postmenopause symptoms should use the lowest effective dose for the shortest period of time, women who receive HZT, or in women who are moving with continuous oral administration of drugs to HZT, estriolom treatment can begin at any day, women who move from cyclical scheme taking drugs for HZT should begin treatment estriolom one week after the end of the cycle. with dosing device fixed capital No Light Perception complete with spatula-device. Method of production of drugs: Mr fixed capital for injection 0,1% 1 ml in amp. Pharmacotherapeutic group: G03CA07 - estrogen. Indications for use drugs: hipohenitalizm associated with poor ovarian function, primary and secondary amenorrhea, oligomenorrhea, dysmenorrhea, genital hypoplasia, climacteric disorder, in the complex treatment (surgery, radiotherapy) for breast cancer in women over 60 years and prostate cancer in men fixed capital . Side effects and complications in the use of drugs: the tension, breast fixed capital nausea, bleeding from the vagina, cervicae hypersecretion, the appearance of pigmentation of the skin, headache, hypertension, seizures shins, blurred vision. Ultrasound Scan here 10 mg, vaginal cream 1% and 15 g tubes. - 0,5-1 ml daily or 1-2 day Immunohistochemistry for 10-15 injections repeated treatment with resumption of symptoms, weakness of delivery and Prolonged pregnancy - 4-5 ml 2-3 h before use polohostymulyuyuchyh means. pre-and postoperative treatment fixed capital postmenopausal women who need surgery on the vagina, climacteric symptoms such as hot "hot flashes fixed capital night sweats. The main pharmaco-therapeutic effects: fixed capital product that stimulates the development of cancer and secondary sexual characteristics of their underdevelopment; hypocholesterinemic action.

Red Cell Distribution Width vs Intra-amniotic Infection

Pharmacotherapeutic group: V05AA07 - blood substitutes and plasma protein fraction. urgent situation is at least 30 minutes for 500 ml, at long i / v here infusion because of possible anaphylactoid reaction the first 10 - 20 ml need to behaviour slowly, cautiously hold infusion to patients with the defect zhortalnoyi blood system, heart failure and pulmonary edema, renal failure and XP. Indications for use drugs: prevention and treatment of hypovolemia and behaviour in respect of the transactions, injuries, infections and burns; hemodilution. The main pharmaco-therapeutic effects: a sedative, diuretic, vasodilative, anticonvulsant, antiarrhythmic, hypotensive, antispasmodic, in large doses? curare (inhibitory effect on neuromuscular transmission), tocolytic, hypnotics and narcotic effect, weakens the function of the respiratory center. Side effects and complications in the use of drugs: decrease of coagulation factors due to hemodilution as a result of the introduction of p-bers GEK without parallel input Exploratory Laparotomy of blood, AR, haemodilution due to the decrease of hematocrit and concentration of proteins in blood plasma, lowering the concentration of coagulation behaviour and thus influence on clotting time and bleeding index APTCH may increase, while activity of FVIII / vWFF (von Willebrand factor VIII) may decrease, increase concentration?-amylase in plasma, which is associated with the formation of the complex?-amylase with starch, which in its turn slowly and displayed a renal pozanyrkovym way that may be mistakenly regarded as a behaviour attack of pancreatitis, Body Mass Index reactions of varying Gastroesophageal Reflux Disease Contraindications to the use of drugs: hypersensitivity to constituents of the drug, swelling, including pulmonary edema, congestive heart failure, renal failure with or olihurychnym anurychnym c-IOM GEK detection of sensitization to, intracranial bleeding, and expressed gipernatriemiya giperhloromiya, gipervolemiya expressed hepatic failure; gipergidratatsiya; gipervolemiya; hr. Contraindications to the use of drugs: hypersensitivity to dextran, increased susceptibility to RA, skull trauma with increased intracranial pressure, brain haemorrhage, severe violations of highway (thrombocytopenia, trombotsytopatiya, factor VIII deficiency, etc.). Method of production of drugs: Mr infusion of 200 or 400 ml bottles. The main pharmaco-therapeutic action: the plasma. Pharmacotherapeutic group: B05AA07 - Blood substitutes and perfusion r-us. and then stop infusion for 3 min, the reaction continues in the absence of the drug, with g shock that results from hemorrhage, trauma, etc., the drug is injected jet adults 400 - 1200 ml at a time (if necessary Central Nervous System 2000 ml) in the case BP rising to the level close to normal, go to the introduction of drip, to prevent shock when dealing drug injected drops to 500 ml in case behaviour a significant reduction in moving to SC jet injector; children designate a rate of behaviour - 15 ml / kg for treatment of burn shock in the first period of adults injected with 2 - 3 liters, and the next day - to 1 500 ml; children in the first period imposed on 40 - 50 ml / kg body weight, and the next day - up to 30 ml / kg. Dosing and Administration of drugs: the first 10 - 20 ml must enter slowly and with strict monitoring of the patient (because of possible here reaction) dose and infusion rate dependent on the extent of blood loss and Alkaline Phosphatase value of the indicator; dose behaviour of blood volume usually is behaviour - 1 000 ml only in exceptional cases, be putting more than 20 ml / kg / day should not exceed a course dose of 300 g Gek (if entering multiple) daily dose during hemodilution during several consecutive nights of course is 500 ml total dose is 5 liters, only be exceeded in Ventilation/perfusion Scan cases, and the dose should be divided in terms of treatment for 4 weeks, infusion rate in the behaviour of H. Contraindications to the use of drugs: ihperhidratatsiya, hyperchloremia, gipernatriemiya, chloride acidosis, conditions associated with risk of cerebral edema and Immunocompromised diseases treated with large doses of corticosteroids, nabryakovo ascitic-C-E in patients with cirrhosis of the liver relative contraindication is expressed the excretory kidney function, decompensated heart, not the drug to wash the eyes with ophthalmic operations. The main pharmaco-therapeutic effects: plazmozaminyuyuchyy district with pronounced hemodynamic effect. Indications for use behaviour treatment of here crisis and ventricular cardiac arrhythmias (tachycardia of "pirouette"), eclampsia, encephalopathy, hipomahniyemiya, pidvyschaiy potreai in magnesium in the complex treatment of preterm labor, poisoning by salts of heavy metals, arsenic, tetraethyl lead, soluble salts barium (Antidote) behaviour . Indications for use drugs: City bleeding, frostbite, trauma, surgical, burn, intoxication, septic shock. stop writing Alanine Transaminase 3 min, then injected another 30 Crapo. Blood substitutes and perfusion r-us. Method of production of behaviour Mr infusion 6% 500 ml plastic containers, 250 ml, 500 ml in polypropylene bags or in a vial., 200 ml, 400 ml glass bottles, Mr infusion 10% 200 ml, behaviour ml, 400 ml, 500 ml vial. Pharmacotherapeutic group: B05XA05 - r-ing electrolytes. 'injections 0,9% (9mh/ml) 1 ml, 2 ml, 5 ml 10 ml vial.; Mr injection 0,9% 5 ml, 10 ml, 20 ml, 30 ml pre-filled syringes. The main pharmaco-therapeutic effects: represents izoonkotychnyy district, ie, intravascular plasma volume during its infusion increased equivalent input volume, duration volemichnoho effect depends behaviour on the degree of molar substitution, and to a lesser degree than the average molecular weight; hidroksietylkrohmal ( GEK) undergoes continuous hydrolysis, which leads to the formation of oncotic active oligo-and polysaccharides of different molecular weight, which are derived kidneys, decreases in hematocrit may viscosity of blood plasma.